CD4 + and CD8 + T-lymphocyte number as predictive marker of relapse after rituximab treatment in childhood-onset refractory nephrotic syndrome.
Toru KanamoriKoichi KameiMai SatoKentaro NishiMika OkutsuSho IshiwaMasao OguraMayumi SakoKenji IshikuraShuichi ItoPublished in: Clinical and experimental nephrology (2023)
Lower CD4 + and CD8 + cell counts in the early phase after rituximab administration may predict a lower risk of relapse.